INTRODUCTION
============

Regular serum prostate-specific antigen (PSA) evaluations and digital rectal examinations (DRE) are recommended for detecting PCa ([@B1]). However, the serum PSA level is the most widely used marker to detect this cancer in the general population. Because PSA is organ specific, but not disease specific, its use for prostate cancer screening lacks adequate sensitivity ([@B2]). Thus, due to the false-positive results obtained by the PSA test during screening, many patients are subjected to an unnecessary transrectal ultrasound-guided prostatic biopsy (TRUSPB), which is an invasive procedure that can lead to significant morbidity, and even mortality ([@B3], [@B4]).

Recently, various strategies were introduced to improve the sensitivity and specificity of the PSA ([@B5]). In these studies, prostate volume, PSA level and age were clinically significant predictors of positive biopsy findings ([@B5], [@B6]). Patel et al. ([@B7]) developed a novel formula that incorporates age, prostate volume, race and PSA level into a single score for prostate cancer detection. The PSA-age volume (PSA-AV) score is calculated by multiplying the age and prostate volume and then dividing the total by the pre-biopsy PSA. Patel et al. noticed the formula is useful for predicting positive biopsy findings. According to their data, the PSA-AV score was more sensitive in younger patients and in patients with a small prostate volume. They also reported that the PSA-AV score was more specific in older patients and in patients with a large prostate volume. The purpose of the present retrospective study was to evaluate the novel score in predicting positive prostate biopsy findings in Turkey.

MATERIALS AND METHODS
=====================

This retrospective study was based on the data of 5,299 TRUSPB procedures performed between 2005 and 2013 at the Department of Urology of the University Hospital in Manisa and the Clinic of Urology of the Teaching and Research Hospital in Istanbul, Turkey. The indications for performing a TRUSPB were elevated or increasing PSA levels, abnormal DRE findings or a previous abnormal TRUSPB. The database consisted of four variables including age, pre-biopsy PSA level, prostate volume and digital rectal examination information.

TRUSPBs were performed using the LOGIQ machine at both the University Hospital and the Teaching and Research Hospital by the urologists. The prostate volume was calculated using ultrasonography during the TRUSPB. The number of biopsy cores (6-12 cores) was determined by the urologists according to their preference. In patients with an abnormal DRE or ultrasound findings, additional biopsy cores were taken.

A total of 5,063 biopsy records were reviewed. We eliminated those biopsy records that did not have complete data, number of biopsy cores with less than 10, patients who were \<40 years or \>79 years old, and patients who had undergone repeat biopsies. A total of 4,717 biopsy specimens were analysed. The PSA-age volume (PSA-AV) score was calculated by multiplying the age and prostate volume and then dividing the total by the pre-biopsy PSA level ([@B7]).

Patel et al. ([@B7]) stratified the PSA-AV score in intervals of 400, and also analysed the score to determine an effective cut-off score for predicting prostate cancer. The sensitivities and specificities of the PSA AV of 500 and 700 were also analysed since the PSA-AV of 500 or 700 were recommended as a PSA-AV cut-off in their study. Therefore we used PSA-AV of 500 and 700 as cut-off of PSA-AV. The sensitivities and specificities of PSA-AV of 500 and 700 were calculated in the patient groups divided according to age and prostate volume. The sensitivities and specificities of the age-adjusted PSA levels and PSA cut-off of 4ng/mL were calculated. For the age-adjusted PSA data, patients were categorized into four categories, each with its own abnormal PSA value. The abnormal values were \>2.5ng/mL (age 40-49 years), \>3.5ng/mL (age 50-59 years), \>4.5ng/mL (age 60-69 years), and \>6.5ng/mL (age 70-79 years). Statistical analyses were carried out using SPSS 13.0 (SPSS Inc.). The study protocol was approved by the ethics committee of our institution.

RESULTS
=======

The mean age of the patients in our study was 63.71±7.63 (n=4,717). The mean PSA level and mean prostate volume were 9.73±17.01ng/mL and 44.46±23.88cm^3^, respectively (10% trimmed mean). Of the 4,717 prostate biopsies, 1,171 biopsy specimens (24.8%) were positive for prostate cancer.

The sensitivities and specificities of the PSA-AV scores in intervals of 400, PSA-AV of 500 and 700, and PSA cut-off of 4ng/mL are shown in Figure-1. The positive predictive value of the PSA-AV cut-off of 500 and 700 was 30% and 27%, respectively. The positive predictive value of the PSA cut-off of 4ng/mL and the age-adjusted PSA method was 26% and 25%, respectively. Although using a PSA-AV cut-off of 700 decreased the number of biopsies by 114, it led to 10 more detected cancer cases compared to using the PSA cut-off of 4ng/mL. In the same population, using a PSA cut-off of 4ng/mL increased the biopsies taken by 875 compared with a PSA-AV cut-off of 500 and led to 95 more detected cancer cases. The sensitivity, specificity, positive predictive and negative predictive value changes within the age and prostate volume groups are listed in [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}.

###### Sensitivity and specificity of various cut-off methods in different age groups.

  Variable              Total biopsies (n)     Cancers detected (n)   Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)   
  --------------------- ---------------------- ---------------------- ----------------- ----------------- --------- --------- ------
  **Age 40-49 years**                                                                                                         
                        Psa cut off 2.5ng/mL   120                    12                85.7              6.1       10.0      77.8
                        Psa cut off 4.0ng/mL   91                     9                 64.3              28.7      9.9       86.8
                        Psaav cut off 700      123                    14                100               5.2       11.4      100
                        Psaav cut off 500      108                    13                92.9              17.4      12.0      95.2
  **50-59 years**                                                                                                             
                        Psa cut off 3.5ng/mL   1191                   199               91.7              12.0      16.7      88.2
                        Psa cut off 4.0ng/mL   1081                   192               88.5              21.1      17.8      90.5
                        Psaav cut off 700      1224                   213               98.2              10.3      17.4      96.7
                        Psaav cut off 500      1005                   194               89.4              28        19.3      93.2
  **60-69 years**                                                                                                             
                        Psa cut off 4.5ng/mL   1767                   445               89.6              15.9      25.2      82.8
                        Psa cut off 4.0ng/mL   1908                   472               95.0              8.7       24.7      84.5
                        Psaav cut off 700      1764                   474               95.5              17.9      26.9      92.5
                        Psaav cut off 500      1408                   424               85.3              37.4      30.1      89.0
  **70-79 years**                                                                                                             
                        Psa cut off 6.5ng/mL   912                    375               84.7              26.6      44.1      74.1
                        Psa cut off 4.0ng/mL   1128                   430               97.1              4.6       38.1      72.3
                        Psaav cut off 700      983                    412               93.0              22.0      41.9      83.9
                        Psaav cut off 500      812                    377               85.1              40.6      46.4      81.8

**PPV** = Positive predictive value; **NPV** = Negative predictive value; **PSA** = prostate-specific antigen; **PSA-AV** = PSA-age volume.

###### Sensitivity and specificity of PSA-AV cut-off of 700 and 500, and PSA cut-off of 4ng/mL in different prostate volume groups.

  Variable                          Total biopsies (n)     Cancers detected (n)   Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)   
  --------------------------------- ---------------------- ---------------------- ----------------- ----------------- --------- --------- -------
  **Prostate volume \<20cm^3^**                                                                                                           
                                    Psa cut off 4.0ng/mL   298                    139               90.8              25.4      46.6      79.4
                                    Psaav cut off 700      345                    151               98.7              8.9       43.8      90.5
                                    Psaav cut off 500      341                    151               98.7              6.3       44.3      92.0
  **Prostate volume 20-60cm^3^**                                                                                                          
                                    Psa cut off 4.0ng/mL   2914                   821               94.0              14.2      28.2      86.9
                                    Psaav cut off 700      3072                   849               97.3              8.8       27.6      90.0
                                    Psaav cut off 500      2555                   778               89.1              27.1      30.5      87.4
  **Prostate volume 60-100cm^3^**                                                                                                         
                                    Psa cut off 4.0ng/mL   786                    116               100.0             5.4       14.8      100.0
                                    Psaav cut off 700      553                    91                78.4              34.7      16.5      90.8
                                    Psaav cut off 500      358                    63                54.3              58.3      17.6      88.6

**PPV** = Positive predictive value; **NPV** = Negative predictive value; **PSA** = prostate-specific antigen; **PSA-AV** = PSA-age volume.

DISCUSSION
==========

Significant research efforts are ongoing to identify the optimal PSA threshold to recommend a prostate biopsy in an asymptomatic patient ([@B5], [@B8]). Catalona et al. reported this PSA level or higher was appropriate as the PSA cut-off value for the screening of PCa. Since then, this value has been the most commonly used clinically. While its sensitivity is 67.5% to 80%, the specificity is only 20% to 30% ([@B9]). Although PSA is a highly organspecific marker, it is not a cancer-specific marker. Therefore, it may also show increases with age or other benign conditions, including benign prostate hyperplasia or prostate inflammation ([@B10]). Prostate-specific antigen density (PSAD) was investigated to decrease the impact of prostate volume on the PSA level before deciding on a TRUSPB. Because studies using PSAD for prostate cancer screening have led to conflicting results, it is not widely used by clinicians ([@B11]). PSA-AV was developed by Patel et al. to correct the impact of prostate volume on PSA levels ([@B7]). They noticed that a PSA-AV score of 700 was a useful formula for predicting positive biopsy findings in patients with small prostates. According to their data, in patients with low to moderate prostate volumes (\<20cm^3^ and 20-60cm^3^), a PSA-AV cut-off of 700 had sensitivities of 97% and 91%, respectively compared with sensitivities of 74% and 86% for a PSA cut-off of 4ng/mL. This makes it useful for ruling out prostate cancer. In patients with low to moderate prostate volumes (\<20cm^3^ and 20-60cm^3^) in our study, a PSA-AV cut-off of 700 had sensitivities of 98% and 97%, respectively. The sensitivities of the PSA cut-off of 4ng/mL were 91% and 94%, respectively, in the same patient group. In both studies, the sensitivities of the PSA-AV cut-off of 700 were higher than the sensitivities of the PSA cut-off of 4ng/mL. However, the sensitivities of the PSA cut-off of 4ng/mL in our study were higher compared with their study. Although their study had 687 patients (prostate volume \<60cm^3^) receiving a TRUSPB, our study had 3,417 patients. Therefore, we think that our data is statistically more reliable. Our findings suggest that, although the sensitivities of PSA-AV cut-off of 700 in patients with low prostate volumes (\<20cm^3^) are higher than with a PSA cut-off of 4ng/mL, the sensitivities of the two methods in patients with moderate prostate volumes (20-60cm^3^) are similar.

Considering all of the biopsies, we found that the sensitivities of a PSA-AV cut-off of 700 and a PSA cut-off of 4ng/mL were 95% and 94%, respectively. Positive predictive values of a PSA-AV cut-off of 700 and a PSA cut-off of 4ng/mL were 27% and 26%, respectively. According to our data, the effectiveness of the PSA-AV cut-off of 700 compared with a PSA cut-off of 4ng/mL are similar for predicting positive biopsy findings, considering all age groups and prostate volumes. Compared with using the PSA cut-off of 4ng/mL, using the PSAAV of 700 decreased the number of biopsies by 114; however, it detected 45 more cancer cases. Patel et al. ([@B7]) noticed that using a PSA-AV cut-off of 700, rather than a PSA cut-off of 4ng/mL, led to 16 fewer biopsies with seven additional cancers detected.

Our data showed that in the 60-69-year-old population, the sensitivities of an age-adjusted PSA, a PSA cut-off of 4ng/mL and a PSA-AV cut-off of 700 were 90%, 95% and 95%, respectively. In this age group, the diagnostic values of these three methods for predicting positive prostate biopsy findings are similar to each other. In patients younger than 60, the sensitivity of the PSA-AV cut-off of 700 was higher than the age-adjusted PSA and the PSA cut-off of 4ng/mL ([Table-1](#t1){ref-type="table"}). In the 50-59-year-old population, the sensitivities of the PSA cut-off of 4ng/mL, the PSA cut-off of 3.5ng/ mL and a PSA-AV cut-off of 700 were 88%, 91% and 98%, respectively. In this group, compared with using the PSA cut-off of 4ng/mL, using PSA-AV cut-off of 700 led to 143 more biopsies and 21 more cancer cases detected. Although the effectiveness of a PSA-AV cut-off of 700 in patients aged over 60 is similar to the other methods, in patients under 60 years old its effectiveness seems higher. Similarly, Patel et al. ([@B7]) suggest that a PSA-AV score of 700 is useful in ruling out cancer in younger patients.

US Preventive Services Task Force noticed that the amount of overdiagnosis of prostate cancer is an important concern because a man with cancer that would remain asymptomatic for the remainder of his life cannot benefit from screening or treatment ([@B12]). One of the limitations of our study was that we did not divide the patients into groups according to their Gleason score. Therefore we could not assess overdiagnosis of PCa and insignificant cancer in our study population. We suggest that further studies should evaluate the effect of PSA-AV formula on insignificant prostate cancer and overdiagnosis.

CONCLUSIONS
===========

Our data supports the findings from the previous study that developed PSA-AV formula. However, in patients with a moderate prostate volume (20-60cm^3^), we did not determine any superiority of the PSA-AV formula. Therefore, we suggest that the PSA-AV cut-off of 700 be used for predicting positive prostate biopsy findings in patients under the age of 60 and with low prostate volumes (\<20cm^3^). Further studies should evaluate the effectiveness of PSA and PSA-AV for predicting positive prostate biopsy findings in the patients without abnormal DRE.
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